Revance Therapeutics
RVNC
$3.32
Share price
-22.61%
Change (1 day)
-90.71%
Change (1 year)
Categories
Revance Therapeutics (RVNC) - P/B ratio
P/B ratio as of May 2024 : -2.13
According to Revance Therapeutics's latest financial reports the company has a price-to-book ratio of -2.13.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Revance Therapeutics - P/B ratio (from 2014 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | -5.09 | -104.22% |
| 2022-12-31 | 121 | 604.39% |
| 2021-12-31 | 17.1 | 239.6% |
| 2020-12-31 | 5.04 | 33.67% |
| 2019-12-31 | 3.77 | -26.25% |
| 2018-12-31 | 5.11 | 5.71% |
| 2017-12-31 | 4.84 | 45.05% |
| 2016-12-31 | 3.33 | -12.64% |
| 2015-12-31 | 3.82 | 67.1% |
| 2014-12-31 | 2.28 | |
| 2013-12-31 | N/A | |
| 2012-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.14 | -340.73% | 🇺🇸 USA |
 Biogen BIIB | 2.12 | -199.36% | 🇺🇸 USA |
 MediciNova MNOV | 1.19 | -155.62% | 🇺🇸 USA |